LongBio Pharma

What LongBio Pharma does

LongBio Pharma (legal name LongBio Pharma (Suzhou) Co., Ltd.) is a clinical-stage biopharmaceutical company headquartered in Shanghai with R&D and manufacturing operations in Changshu, Suzhou, China. Founded in 2020 and listed on the Hong Kong Stock Exchange on June 5, 2026 under stock code hkg:1779, the company is focused on in-house discovery and development of biologics for allergic and autoimmune diseases, including IgE-mediated conditions (seasonal allergic rhinitis, chronic spontaneous urticaria, allergic asthma, chronic rhinosinusitis with nasal polyps, food allergy) and complement-mediated disorders (PNH, IgA nephropathy, lupus nephropathy, C3 glomerulopathy, ALS, generalized myasthenia gravis).

The company's pipeline is built on three proprietary technology platforms: the Sundoma™ High-affinity Antibody Discovery Platform, which has produced picomolar-affinity antibodies including LP-003 (KD 2.08 pM, roughly 860-fold greater IgE binding affinity than omalizumab); the NeXine™ Long-acting Cytokine Technology Platform, which uses Fc-fusion protein engineering to extend dosing intervals for growth hormone, EPO, and coagulation factor VIII; and the InCibitor™ Bi-functional Antibody Development Platform, which produced LP-005, described as the first Q4W bi-functional complement inhibitor globally. The lead asset LP-003 is positioned as the first novel anti-IgE antibody to file for marketing in more than 20 years since omalizumab, with positive Phase II CSU head-to-head data against omalizumab and an NMPA BLA submission planned for Q3 2026 in seasonal allergic rhinitis.

LongBio is pre-revenue and generates no product sales today; its business model contemplates future commercialization of LP-003 and LP-005 through pharmaceutical distribution in China and internationally with partners, targeting regulatory approvals from NMPA and the US FDA. The company has raised approximately USD 70M+ across six disclosed financing rounds from 2021 through 2025, led or co-led by Qiming Venture Partners (which held a 4.27% pre-IPO stake), and at IPO carried a HK$10.7 billion market capitalization on a small 11–50 employee footprint.

Name

LongBio Pharma

Legal name

LongBio Pharma (Suzhou) Co., Ltd.

Website

https://longbio.com

Company type

Public

Founded year

2020

Operating status

Ipo

Headcount range

11–50 employees

Short description

LongBio Pharma is a clinical-stage Chinese biopharmaceutical company developing proprietary biologics, led by LP-003 (next-generation anti-IgE antibody) and LP-005 (bi-functional complement inhibitor), for patients with allergic and autoimmune diseases in China and international markets.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals — Allergy and Autoimmune Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Biopharmaceutical drugs
• Allergic disease therapeutics
• Autoimmune disease treatments
• Monoclonal antibodies
• Complement inhibitors

Headquarters

HQ city

Pudong

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Biopharmaceutical Product Sales: Pre-revenue clinical-stage biotech company developing innovative biologics. Revenue will come from commercializing pipeline products (LP-003 for allergies, LP-005 for complement-mediated diseases) upon regulatory approval. Plans to serve both domestic (China) and international markets with partners, offering affordable high-quality bio-medicines.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

LongBio Pharma is a clinical-stage biopharmaceutical company that discovers and develops innovative biologics targeting IgE-mediated allergic diseases and complement-mediated autoimmune disorders. Its core pipeline assets include LP-003 (next-generation anti-IgE monoclonal antibody) and LP-005 (C5xC3b bi-functional complement inhibitor), supported by proprietary platforms Sundoma™, InCibitor™, and NeXine™. The company plans to commercialize approved products via distribution partners in domestic (China/NMPA) and international (US FDA) markets.

Product overview

LongBio Pharma is a clinical-stage biopharmaceutical company developing a comprehensive pipeline of biologics for allergic and autoimmune diseases. The core products include LP-003 (next-generation anti-IgE antibody) and LP-005 (C5xC3b bi-functional complement inhibitor), supported by Sundoma™ high-affinity antibody discovery platform and NeXine™ long-acting cytokine technology platform. Additional pipeline products include LP-001 (long-acting EPO-Fc), LP-002 (long-acting growth hormone-Fc), and bi-functional antibodies LP-00A, LP-00C, and LP-00D targeting various therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

• Sundoma: High-affinity Antibody Discovery Platform that produces antibodies with significantly improved affinities surpassing traditional methods.
• InCibitor
• NeXine

Products and services

• LP-003 Next-generation anti-IgE monoclonal antibody for treating IgE-mediated allergic diseases including seasonal allergic rhinitis, chronic spontaneous urticaria (CSU), allergic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and food allergy. Demonstrates 860-fold greater IgE binding affinity (KD 2.08 pM vs 1790 pM for omalizumab), 30-fold higher blocking activity, and a 45-76 day half-life enabling Q8W dosing.
• LP-005 C5xC3b bi-functional antibody fusion protein (complement inhibitor) for treating complement-mediated diseases including paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy (IgAN), lupus nephropathy (LN), C3 glomerulopathy (C3G), ALS, generalized myasthenia gravis (gMG), and myelin-associated glycoprotein neuropathies (MAG-PN). First Q4W bi-functional complement inhibitor globally.
• LP-001 (long-acting EPO-Fc) Long-acting erythropoietin Fc-fusion protein for treating myelodysplastic syndrome (MDS) and chronic kidney disease anemia (CKD Anemia), leveraging the NeXine™ platform for extended Q4W dosing.
• LP-002 (long-acting growth hormone-Fc) Long-acting growth hormone Fc-fusion protein for treating growth hormone deficiency (GHD) with Q2W-Q4W dosing intervals enabled by the NeXine™ platform.
• LP-00A Bi-functional antibody with undisclosed target for treating allergic diseases, developed using the InCibitor™ bi-functional antibody development platform.
• LP-00C Bi-functional antibody or fusion protein targeting B lymphocyte-mediated autoimmune diseases, developed using the InCibitor™ bi-functional antibody development platform.
• LP-00D Bi-functional antibody or fusion protein targeting complement-related indications, developed using the InCibitor™ bi-functional antibody development platform.

Quantifiable outcome

• 66.7% UAS7=0 response rate at Week 12 for LP-003 200mg Q8W vs 43.6% for omalizumab (p=0.0405)
• +4 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Strategic Distribution PartnersminorChannel Partner/ Reseller/ DistributorCompany aims to bring drugs to both domestic and international markets with partners, specifically mentioning partnerships for distributing affordable high-quality bio-medicines. No specific partner names disclosed.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Regional players

• Innovent Biologics: China-based biopharmaceutical company developing innovative biologics including immuno-oncology and autoimmune therapies. Comparable as a Chinese clinical-stage biotech with Hong Kong listing and biologics pipeline.
• BeiGene: Leading China-headquartered biopharmaceutical company with Hong Kong and US listings, focused on oncology and immunology biologics. Comparable China-origin biotech with global ambitions and platform-based R&D.
• HUTCHMED (China) Limited: Hong Kong-listed clinical-stage biopharmaceutical company with similar China-origin innovation profile. Comparable as a fellow HKEX-listed Chinese biotech advancing innovative therapies globally.

Broad incumbents

• Sanofi: Through its Dupixent (dupilumab) franchise with Regeneron, Sanofi is a broad incumbent in allergic and immunological diseases including asthma, CRSwNP, and CSU—directly competing with LP-003's target indications.
• Regeneron Pharmaceuticals: Co-developer of Dupixent (dupilumab) and an antibody engineering leader. Comparable in biologics R&D capability and direct competitive overlap in allergic disease indications targeted by LP-003.

Direct peers

• Genentech (Roche): Co-developer and global marketer of omalizumab (Xolair®), the incumbent anti-IgE therapy that LP-003 is positioned against. Genentech/Roche is the most directly comparable peer given the head-to-head nature of LP-003's development program.
• Novartis: Co-marketer of omalizumab (Xolair®) alongside Genentech in non-US markets and active developer of biosimilars and next-generation allergy biologics. Direct comparable in the allergy/respiratory biologics space.
• AstraZeneca (Alexion): Market leader in complement inhibitor therapeutics (Soliris®, Ultomiris®) for PNH and other complement-mediated diseases. LP-005 directly targets this therapeutic space with a bi-functional mechanism.
• Apellis Pharmaceuticals: Developer of Empaveli/Aspaveli (pegcetacoplan), a C3 complement inhibitor for PNH. Competes directly with LP-005's complement-mediated disease indications and represents the new wave of complement therapeutics.

Emerging players

• BioCryst Pharmaceuticals: Developer of innovative small-molecule and biologic therapies for rare immunological diseases, including complement-mediated hereditary angioedema. Comparable as a clinical-to-commercial biotech focused on immunology with differentiated therapeutic profiles.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/longbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds7 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LongBio Pharma